Abstract The norepinephrine transporter (NET) is the carrier that drives the neuronal norepinephrine uptake mechanism (uptake 1 ) in mammalian hearts. The radioligand [ 3 H]mazindol binds with high affinity to NET. In this study, the kinetics of [ 3 H]mazindol binding to NET were measured using a rat heart membrane preparation. Results from these studies were used to set up saturation binding assays designed to measure cardiac NET densities (B max ) and competitive inhibition assays designed to measure inhibitor binding affinities (K I ) for NET. Saturation binding assays measured NET densities in rat, rabbit, and canine hearts. Assay reproducibility was assessed and the effect of NaCl concentration on [ 3 H]mazindol binding to NET was studied using membranes from rat and canine hearts. Specificity of [ 3 H]mazindol binding to NET was determined in experiments in which the neurotoxin 6-hydroxydopamine (6-OHDA) was used to selectively destroy cardiac sympathetic nerve terminals in rats. Competitive inhibition studies measured K I values for several NET inhibitors and substrates. In kinetic studies using rat heart membranes, 
H]mazindol binding to NET was determined in experiments in which the neurotoxin 6-hydroxydopamine (6-OHDA) was used to selectively destroy cardiac sympathetic nerve terminals in rats. Competitive inhibition studies measured K I values for several NET inhibitors and substrates. In kinetic studies using rat heart membranes, [ 3 values. These studies demonstrate the high selectivity of [
Introduction
The autonomic nervous system plays a central role in the regulation of cardiac function. Abnormalities of cardiac autonomic innervation have increasingly been implicated as a major underlying factor contributing to the high morbidity and mortality associated with sudden cardiac death (Schwartz 1998) , congestive heart failure (Packer 1992) , diabetic autonomic neuropathy (Ewing 1996) , myocardial ischemia (Armour 1998 ) and cardiac arrhythmias (Zipes 1995) . With more than 300,000 deaths/year in the United States attributed to sudden cardiac death alone (Virmani et al. 2001) , increasing our understanding of the role of autonomic dysfunction in these diseases is an important research goal.
In an effort to provide clinicians with better tools for investigating autonomic dysfunction, several radiotracers have been developed at our institution for non-invasive imaging studies of the sympathetic branch of cardiac autonomic innervation. Radiotracers that have been successfully used as markers of cardiac sympathetic neurons include the single-photon imaging agents [
131 I] meta-iodobenzylguanidine and [
123 I]meta-iodobenzylguanidine (MIBG; Wieland et al. 1981) , and the positron emission tomography (PET) radiotracers [ 11 C]meta-hydroxyephedrine (HED; Rosenspire et al. 1990) , [ 11 C]epinephrine (Chakraborty et al. 1993) , and [ 11 C]phenylephrine (Del Rosario et al. 1996) . All of these imaging agents are transported into sympathetic neurons by the neuronal norepinephrine transporter (NET) and subsequently stored in vesicles by the vesicular monoamine transporter (VMAT; Raffel and Wieland 2001) .
As part of our ongoing efforts to characterize and validate these radiotracers in animal models, we were interested in implementing an in vitro assay to measure NET density in heart tissue samples. Measurements of cardiac NET density in mammalian heart tissue samples have previously been reported by several laboratories, using [ 3 H]mazindol (Liang et al. 1989; Böhm et al. 1995; Ungerer et al. 1996; Mardon et al. 2003) (Raisman et al. 1982; Kiyono et al. 2002a; Kiyono et al. 2002b), or [ 3 H]nisoxetine (Böhm et al. 1998; Leineweber et al. 2000) as the radioligand in saturation binding assays. Cardiac NET density (B max ) values measured for a given mammalian species tend to vary from laboratory to laboratory due to differences in the methods used for tissue homogenization, subsequent tissue processing, and saturation binding assay conditions. Furthermore, there appears to be scant information in the literature regarding the kinetics of radioligand binding to cardiac NET.
The present study was undertaken to characterize the binding of [ ) and the association constant k on (nM
3 H]mazindol binding to NET purified from rat hearts. These parameters were used to establish incubation times for saturation binding assays designed to measure cardiac NET density and for competitive inhibition studies designed to measure equilibrium dissociation constants (K I ) for NET substrates and inhibitors. In addition to control studies, the influence of some experimental conditions on saturation binding assay results, including protein concentration and NaCl concentration, were assessed. The reproducibility of the saturation binding assay was also investigated. The specificity of [ 3 H]mazindol binding to NET was determined in studies in which the neurotoxin 6-hydroxydopamine was used to chemically denervate the heart. Finally, saturation binding assays were performed with canine and rabbit heart tissue to test the ability of the assay to measure NET density and binding affinity in heart samples from other mammalian species.
Materials and methods

Animal care
The care of all animals used in this study was done in accordance with the Animal Welfare Act and the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (National Research Council 1985) . Animal protocols were approved by the University Committee on Use and Care of Animals (UCUCA) at the University of Michigan.
Membrane preparations Differential centrifugation of homogenized heart tissue was used to obtain a membrane preparation enriched in NET. The buffer solution used for tissue homogenization (buffer A) was 5 mM Tris-base (pH 7.4) containing 1 mM MgCl 2 and 250 mM sucrose. For most studies, the buffer solution used for the final membrane preparation and for binding assays (buffer B) was 50 mM Tris-base (pH7.4) containing 5 mM KCl and 100 mM NaCl. For rat heart studies, male Sprague-Dawley rats (225-350 g) were anesthetized with ether, a bilateral thoracotomy performed, and the heart surgically removed and placed in a 100-ml beaker containing icecold buffer A. The heart chambers were cut open and rinsed of blood. After the aorta and excess vascular tissue were removed the heart was blotted dry and weighed, then placed in a 100-ml beaker containing 10 ml of ice-cold buffer A. The heart was minced with scissors and transferred with the buffer to an ice-chilled 30-ml borosilicate glass test tube. The heart pieces were homogenized using a Brinkmann Polytron with a 12-mm sawtooth generator (PT10/35, with Kinematica PCU-2-110 controller, Brinkmann, Westbury, NY, USA) kept at 4°C in a cold room. Homogenization was performed on setting 7 for 30 s (3×10-s bursts). The homogenate was centrifuged at 1,000 g (max) for 15 min at 4°C. The supernatant fraction (S 1 ) was removed with a polypropylene transfer pipette and placed in a 10 ml polycarbonate ultracentrifugation tube. A fluffy layer of material at the interface between S 1 and the pellet (P 1 ) was discarded with the P 1 fraction. The S 1 fraction was centrifuged at 100,000 g (max) for 30 min at 4°C. The supernatant fraction (S 2 ) was discarded and 1 ml of ice-cold buffer B was added to the tube. The pellet (P 2 ) was removed intact from the tube wall with the tip of a metal spatula and resuspended by repeatedly pipetting the pellet and buffer mixture in and out of a 1.25-ml disposable pipettor (Eppendorf Combitip, Brinkmann Instruments, Westbury, NY, USA) ∼25 times. Another 5 ml of icecold buffer B was added and the tube vortexed until a uniform mixture was achieved. The resuspended P 2 fraction was again centrifuged at 100,000 g (max) for 30 min at 4°C. The supernatant was discarded and the pellet (P 3 ) resuspended in 1 ml buffer B. An additional 5 ml of buffer B was added and the solution vortexed until well mixed. Membrane preparations were frozen at −80°C until used for assays. Protein concentrations in the membrane preparations were measured with the Lowry spectrophotometric method (Lowry et al. 1951 ), using bovine serum albumin for standards.
Binding assays-common methods All assays were performed at room temperature (22°C) in 96-well polystyrene microtiter assay plates fabricated with a special non-binding surface designed to minimize binding of radioligand to the plate wells (Corning COSTAR #3641, Corning Life Sciences, Acton, MA, USA). Typically, total binding of [ 3 H]mazindol to NET in cardiac membranes was determined by incubating 100 μl of membrane preparation (∼100 μg protein), 100 μl of buffer B and 50 μl of buffer B containing [ 3 H]mazindol at the concentration required for a given experiment, for a total reaction volume of 250 μl. To measure non-specific [ 3 H]mazindol binding, identical well contents were prepared except that the 100 μl aliquot of buffer B contained the high affinity NET inhibitor desipramine (DMI) at 25 μM (final DMI concentration 10 μM). During incubation, assay plates were continuously shaken on the tray of a shaking water bath. Assays were terminated by rapid filtration onto Whatman GF/C glass fiber filters using a Brandel cell harvester equipped with a 24-well probe (#M-24T, Brandel, Gaithersburg, MD, USA). The wells and filters were rinsed by filling the wells with ice-cold incubation buffer, followed by filtration, 30 times in rapid succession, for a total rinse volume of ∼15 ml. Filter sheets were soaked in ice-cold incubation buffer prior to use. Individual filters were placed in 20 ml glass scintillation vials along with 10 ml of scintillation cocktail (UniverSol ES, ICN Biomedicals, Irvine, CA, USA). Vials were shaken on an orbital shaker for 1 h and then allowed to stand overnight. The next morning the activity in each vial was determined by liquid scintillation spectrometry. Specific Kinetics studies Hearts from 12 rats were processed in parallel as described above and their final membrane preparations combined. This was done twice to yield two batches of membranes with homogeneous NET density. Each kinetic study required the use of two hearts worth of membrane preparation. Six association experiments and six dissociation experiments were performed, three each from the two batches of homogenous membrane preparation.
Saturation binding assays Control studies were performed using an age-matched group of six rats (Group I). To determine assay reproducibility, eight age-matched rats were used to prepare two batches of membrane preparation with uniform NET density (Group II). For the first batch, the resuspended pellets from the initial centrifugation at 100,000 g were combined, vortexed, and divided into equal fractions before performing the final 100,000 g centrifugation ("P 2 combined"; n=4). For the second batch, the final membrane preparations were combined, vortexed, and divided into equal fractions ("P 3 combined"; n=4). To assess the influence of the protein concentration used in the assay, hearts from an age-matched group of eight rats were individually processed and their final membrane preparations combined to achieve a uniform NET density (Group III). Saturation assays were performed using either 50 μg protein/well (n=4) or 100 μg protein/well (n=4). To determine the influence of the Na + concentration in the assay buffer on [ 3 H] mazindol binding to NET, hearts from 12 age-matched rats (Group IV) were homogenized and centrifuged at 1,000 g for 15 min. The S 1 fractions from all 12 hearts were combined, mixed, and divided into 12 equal aliquots before being put through the final centrifugation steps (100,000 g for 30 min, twice). The final pellets were resuspended in 50 mM Tris-base (pH 7.4) containing 5 mM KCl and one of three NaCl concentrations: 100, 200 or 300 mM (n=4 each).
Specificity of [
3 H]mazindol for NET To validate that [ 3 H]mazindol was binding specifically to NET on sympathetic neurons, saturation assays were performed in rat hearts that had varying degrees of denervation induced chemically by in vivo administration of the neurotoxin 6-hydroxydopamine (6-OHDA). Fifteen age-matched rats were divided into five groups (n=3 each). Each group received a different injected dose of 6-OHDA: 0 (controls), 3, 10, 30 and 100 mg/kg. Doses of 6-OHDA were administered i.p. in 0.7-0.8 ml sterile 0.9% sodium chloride injection USP, 24 h prior to heart removal.
Dog and rabbit heart studies Hearts were harvested immediately post-mortem from six female adult mongrel dogs and three female New Zealand White rabbits that had been used for kidney imaging experiments in a neighboring laboratory. These animals had been anesthetized for 4.5-10 h prior to their death. Dogs were anesthetized with 15-23 mg acepromazine maleate s.c., then 6-12 ml pentothal 5% i.v., followed by continuous administration of 1-1.5% isoflurane. Rabbits were anesthetized with 17-19 mg xylazine i.m., then 120-130 mg ketamine i.m., followed by continuous administration of 1-2% isoflurane. Hearts were surgically removed and placed in a large beaker of ice-chilled sterile 0.9% sodium chloride irrigation solution. The heart chambers were cut open and rinsed of blood. Hearts were dissected into 1-to 3-g pieces, placed in aluminum foil and snap frozen in liquid nitrogen prior to storage at −80°C. The frozen heart pieces were later thawed and left ventricular tissue samples weighing 1.5-2.0 g were minced, homogenized and processed into membrane preparations as previously described for rat hearts. Control saturation binding assays were performed on n=2-4 left ventricular tissue samples from each animal using the same methods described above for rat hearts. The influence of the Na + concentration in the assay buffer was studied in canine heart samples. Twelve left ventricular samples from a single dog heart were homogenized, centrifuged at 1,000 g for 15 min, the S 1 fractions combined, then divided into equal aliquots prior to the final centrifugation steps (100,000 g for 30 min, twice). The final pellets were resuspended in assay buffer containing 100, 200 or 300 mM NaCl (n=4 each).
Chemicals [4′-
3 H]Mazindol (product #NET-816; specific activity 21.0 Ci/mmol) was purchased from Perkin Elmer/New England Nuclear (Boston, MA, USA). Desipramine hydrochloride, (−)-norepinephrine hydrochloride, (−)-epinephrine bitartrate, (−)-phenylephrine hydrochloride, dopamine hydrochloride, (−)-erythrometaraminol bitartrate, (±)-tranylcypromine hydrochloride, guanethidine monosulfate, bretylium tosylate, 5-hydroxytryptamine hydrochloride (serotonin), and all reagents used for preparation of assay buffers were purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). S-(+)-oxaprotiline (CGP 12104A) and R-(−)-oxaprotiline (CGP 12103A) were generous gifts of Novartis Pharma AG, Basel, Switzerland. meta-Iodobenzylguanidine sulfate, para-iodobenzylguanidine sulfate, (−)-erythro-meta-hydroxyephedrine hydrochloride, (−)-meta-octopamine, and methcathinone were synthesized in our laboratory. Sterile solutions of 0.9% sodium chloride were purchased from Abbott Laboratories (North Chicago, IL, USA).
Data analysis and statistics
The measured data from all binding studies were fit to the appropriate kinetic or equilibrium binding equation (Hulme and Birdsall 1992) using the non-linear regression analysis program GraphPad Prism (GraphPad Software, San Diego, CA, USA). Statistical tests for significant differences between measurements were performed using Student's two-tailed t-test for two samples with equal variance, with p values <0.05 considered to be significant. H]mazindol binding to rat heart NET, data from association and dissociation studies were all well described by single exponential processes (Fig. 1) . The dissociation rate constant k off was measured to be 0.0123±0.0007 min −1 (n=6). The association constant k on was measured to be 0.0249±0.0019 nM 
Saturation binding assays
Saturation binding assays were performed to measure cardiac NET density (B max ) and the equilibrium dissociation constant K D . Binding parameters determined from the saturation assays performed with rat heart membranes are summarized in Table 1 . Representative data from a control saturation binding assay (Group I) are shown in Fig. 2 . The specific binding of [ 3 H]mazindol to NET was saturable and monophasic in all cases. Binding parameters measured in assays in which the pellets from the first or second centrifugation at 100,000 g were combined (Table 1 ; Group II) were comparable to the control studies, but the B max values had lower coefficients of variation than the controls.
For assays comparing 50 μg protein/well with 100 μg protein/well (Table 1 ; Group III), the estimated binding parameters for the two protein concentrations were not statistically different, but the coefficients of variation in the binding parameters for the 50 μg protein group were higher than those of the 100 μg protein group.
For the rat heart assays done with increasing concentrations of NaCl in the assay buffer (Table 1 ; Group IV), the measured B max values were significantly higher for 300 mM NaCl than for 100 mM NaCl (p<0.01) and 200 mM NaCl (p<0.004). Increasing NaCl concentration also lead to significant increases in the binding affinity of ). While the B max values measured for 100 mM NaCl studies averaged ∼ 15% higher than the control values measured for Group I, this increase did not reach statistical significance.
NET density (B max ) measurements made in hearts from rats injected with 6-OHDA are shown in Fig. 3 . NET density decreased in a dose-dependent manner from a control value of 533±54 fmol/mg protein to 40±1 fmol/mg protein for the highest injected dose (100 mg/kg i.p.), a reduction of 92%. Fitting the data to a sigmoidal doseresponse function with variable slope yielded an estimated EC 50 of 12.4±0.5 mg/kg and Hill slope of −2.77±0.32.
Cardiac NET densities in canine and rabbit hearts were measured for comparison with the results from rat hearts. In left ventricular samples from canine hearts, NET densities were found to be higher than those measured in rat hearts (Table 2 ). Also, [ 3 H]mazindol exhibited lower binding affinity to NET (higher K D values) in canine heart than in rat heart. NET densities in rabbit hearts were found to be lower than the values measured in rat hearts ( H]mazindol to NET in rat heart membrane preparations. Membranes were incubated at 22°C for 90 min in the absence (total binding) or presence (nonspecific binding) of 10 μM desipramine to determine specific binding at eight [ heart NET was lower than the affinities seen in rat heart and canine heart. Similar to the results in rat heart, increasing the NaCl concentration in the assay buffer increased the measured NET density in canine hearts (Table 2 ; Dog 6). B max values for 200 mM NaCl and 300 mM NaCl were significantly higher than for 100 mM NaCl (p<0.003 for both comparisons). B max values for 200 and 300 mM NaCl were not significantly different. Binding affinity increased (i.e., K D values decreased) with increasing NaCl concentration, with significant changes between 100 and 200 mM NaCl (p<1.2×10 ) and between 200 and 300 mM NaCl (p<1.7×10 −8 ).
Competitive inhibition assays
Competitive inhibition assays were performed using rat heart membrane preparations to measure the equilibrium dissociation constants (K I ) of several NET inhibitors and substrates (Table 4) . Representative competition curves are shown in Fig. 4 . The curves were all well described by a monophasic inhibition process and in most cases the Hill slopes were close to unity.
Discussion
Kinetic studies
One of the main goals of this study was to characterize the kinetics of [ , corresponds to a half-time (t 0.5 ) of 56.3 min. Typically it is recommended that the incubation time used in a saturation binding assay be set at five times the t 0.5 of radioligand dissociation (Hulme and Birdsall 1992) . This ensures that binding has reached at least 97% of the final equilibrium values at all concentrations of radioligand used in the assay. For [ 3 H]mazindol, this implies that an Fig. 3 Cardiac NET density (B max ) in rat heart membranes as a function of injected 6-hydroxydopamine (6-OHDA) dose. 6-OHDA was injected i.p. into rats 24 h prior to heart removal and processing into membrane preparations. Values plotted are the means ± SD (n=3 each) of the NET densities measured for each heart using saturation binding assays Values are means ± SD Table 4 . DMI desipramine, MIBG meta-iodobenzylguanidine, HED meta-hydroxyephedrine, NE norepinephrine incubation time of 282 min would be necessary to meet this criteria. However, we chose to use a shorter incubation time of 90 min in our saturation binding assays since we were mainly interested in measuring cardiac NET density (B max ) rather than the affinity of [ Similarly, for competition binding assays, it is recommended that the incubation time be set to five times the t 0.5 of the slowest dissociation process in the assay (Hulme and Birdsall 1992 (Mardon et al. 2003 ). In the assay reproducibility studies in which the resuspended P 2 or P 3 fractions were combined to achieve a uniform NET density in the membrane preparation (Group II, Table 1), the measured B max values were comparable to the control studies. However, B max values were grouped much more tightly than in the control studies. This indicates that the binding assay itself is highly reproducible and suggests that much of the variability in the measured B max values in the control studies is due to animal-to-animal variation in cardiac NET density. For the studies in which two different amounts of membrane preparation were used (Group III, Table 1 ), we found similar binding parameters but the values for 50 μg protein/well had higher coefficients of variation than the values measured using 100 μg protein/well. This is most likely due to the lower counting statistics obtained with the lower protein concentration.
Increasing the NaCl concentration in the assay buffer from 100 mM to 300 mM caused modest increases in B max and increased binding affinity more than twofold in rat heart saturation assays (Group IV, Table 1 ). Binding of [
